[Infostock Daily=Reporter Park Jeong-Do] SK Group shares are drawing attention on the news that SK Bioscience, a vaccine company, has signed an antigen development and CDMO contract with Novavavax, a US bio company, for the novel Coronavirus (Covid-19) vaccine candidate NVX-CoV2373.
The CDMO contract is based on SK Bioscience's transfer of antigen manufacturing technology of NVX-CoV2373, a Corona 19 vaccine candidate under development by NovaBax, and then the production of it at the Andong vaccine plant L House and supply it globally.
SK Bioscience is a subsidiary of SK Chemicals. SK Bioscience holds a 98.04% stake in SK Chemicals. SK Bioscience is an unlisted company.
SK Chemicals closed at 36,000 won, up 9% from the previous trading day on March 13, while SK Discovery finished at 80,000 won, down 1.6%. SK Discovery shares, which were 48,400 won on March 31, climbed to 80,000 won on the 10th, with the upper limit closing.
Reporter Park Jeong-Do newface0301@naver.com
